LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.28 | $0 | -$2.4B |
| 2025 Q2 | -0.31 | $0 | -$1M |
| 2025 Q1 | -0.64 | $0 | -$1M |
| 2024 Q4 | -1.37 | $173,666 | -$990,413 |
| 2024 Q3 | -1.29 | $0 | -$653,103 |
| 2024 Q2 | -0.99 | $0 | -$918,792 |
| 2024 Q1 | -1.31 | $0 | -$1M |
| 2023 Q4 | -0.81 | $449,617 | -$727,710 |